#ESCCongress – [Not Published Yet] First randomized trial backs safety of ACE Inhibitors and ARBs in COVID-19 patients

News Release: First randomised trial backs safety of common heart drugs in COVID-19 patients – European Society of Cardiology

Commentary: Continuing Versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers – BRACE CORONA – American College of Cardiology

Commentary on Twitter

Dr. Renato Lopes presents the BRACE CORONA trial: in patients hospitalized with COVID-19, suspending ACEI/ARB therapy for 30 days did not impact the number of days alive and out of hospital.

Full slide deck: https://t.co/avSK41bGSj#ESCCongress pic.twitter.com/2p0FH9U2RG

— C. Michael Gibson MD (@CMichaelGibson) September 1, 2020